Completed PHASE2 INTERVENTIONAL 1-arm NCT01158534

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining

Sponsor: Case Comprehensive Cancer Center

Conditions Renal Cell Cancer Stage IV Renal Cell Cancer

Interventions celecoxib flow cytometry immunohistochemistry staining method immunologic technique laboratory biomarker analysis polymerase chain reaction recombinant interferon alfa-2b reverse transcriptase-polymerase chain reaction

Updated 6 times since 2017 Last updated: Aug 2, 2012 Started: Mar 31, 2006 Primary completion: Sep 30, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Cell Cancer and Stage IV Renal Cell Cancer and is currently completed. Case Comprehensive Cancer Center leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Comprehensive Cancer Center

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States